2026-04-22T21:56:05Zhttps://uvadoc.uva.es/oai/requestoai:uvadoc.uva.es:10324/620582026-04-09T10:18:04Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Olivares Hernández, Alejandro
Barco Morillo, Edel del
Parra Pérez, Carmen
Miramontes González, José Pablo
Figuero Pérez, Luis
Martín Gómez, Teresa
Escala Cornejo, Roberto
Bellido Hernández, Lorena
González Sarmiento, Rogelio
Cruz Hernández, Juan Jesús
Ludeña de la Cruz, María Dolores
2023-10-18T11:54:46Z
2023-10-18T11:54:46Z
2022
Biomedicines, 2022, Vol. 10, Nº. 2, 360
2227-9059
https://uvadoc.uva.es/handle/10324/62058
10.3390/biomedicines10020360
360
2
Biomedicines
10
2227-9059
Mutations in the mismatch repair (MMR) system predict the response to immune checkpoint inhibitors (ICIs) like colon or gastric cancer. However, the MMR system’s involvement in non-small cell lung cancer (NSCLC) remains unknown. Addressing this issue will improve clinical guidelines in the case of mutations in the main genes of the MMR system (MLH1, MSH2, MSH6, and PMS2). This work retrospectively assessed the role that these gene mutations play in the response to and survival of ICIs in NSCLC. Patients with NSCLC treated with nivolumab as the second-line treatment in the University Hospital of Salamanca were enrolled in this study. Survival and response analyses were performed according to groups of MMR system gene expression (MMR expression present or deficiency) and other subgroups, such as toxicity. There was a statistically significant relationship between the best response obtained and the expression of the MMR system (p = 0.045). The presence of toxicity grade ≥ 3 was associated with the deficiency expression of MMR (dMMR/MSI-H) group (p = 0.022; odds ratio = 10.167, 95% confidence interval (CI) 1.669–61.919). A trend towards greater survival and response to ICIs was observed in NSCLC and dMMR. Assessing the genes in the MMR system involved in NSCLC is key to obtaining personalized immunotherapy treatments.
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
DNA repair
Immunotherapy
Inmunoterapia
Oncology
Cancer research
Immune checkpoint inhibitors (ICIs)
Non small cell lung cancer
Lungs - Cancer
Pulmones - Cáncer
Survival
Supervivencia
Retrospective analysis
Genetics
Genetica
Molecular biology
Influence of DNA mismatch repair (MMR) system in survival and response to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC): Retrospective analysis
info:eu-repo/semantics/article